Skip to main content
TECON BIOLOGY Co.LTD logo

TECON BIOLOGY Co.LTD — Investor Relations & Filings

Ticker · 002100 ISIN · CNE000001PZ9 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,493 across all filing types
Latest filing 2022-10-10 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002100

About TECON BIOLOGY Co.LTD

https://www.tcsw.com.cn

TECON BIOLOGY Co.LTD operates an integrated industrial chain focused on animal health and nutrition. The company specializes in the research, development, and manufacturing of veterinary biological products, including a comprehensive range of vaccines and diagnostic reagents for livestock. Its operations encompass the production of high-quality animal feed and the management of large-scale breeding programs, with a primary focus on pig farming and meat processing. By leveraging advanced biotechnology and standardized production systems, the company provides comprehensive solutions for livestock management and food safety. Key activities include the formulation of specialized animal nutrition products and the implementation of rigorous biosecurity protocols across its facilities to ensure the quality and reliability of its agricultural outputs.

Recent filings

Filing Released Lang Actions
第七届董事会第三十二次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of the resolutions passed at the 32nd meeting of the 7th Board of Directors of Tian Kang Bio Co., Ltd. It includes details about the meeting date, attendance, and voting results on a specific agenda item related to the subsidiary's use of idle funds. The document is a formal disclosure of board decisions and does not contain financial statements or detailed management reports. It fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the company's board of directors or senior management. The document length is short and focused on board resolutions, not a full report or financial data.
2022-10-10 Chinese
中信建投证券股份有限公司关于天康生物股份有限公司子公司使用部分暂时闲置自有资金进行现金管理的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed opinion and verification report from a sponsoring securities company (中信建投证券股份有限公司) regarding the use of temporarily idle funds by a subsidiary of 天康生物股份有限公司 for cash management purposes. It includes descriptions of the investment purpose, types, limits, risk control measures, and approvals by the board, supervisory committee, and independent directors. The document is not a financial report, earnings release, or regulatory filing per se, but rather a formal verification and opinion statement related to a specific financial management activity. It does not contain financial statements or earnings data, nor is it an announcement of voting results or management changes. It is a specialized audit or verification report on a particular financial activity, which fits best under the category of Audit Report / Information (AR). The document length is 2452 characters, which is relatively short but contains substantive content beyond a mere announcement or certification, so it is not RPA or RNS. Therefore, the best classification is AR with high confidence. FY 2022
2022-10-10 Chinese
第七届监事会第二十次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of the resolution passed at the 20th meeting of the 7th Supervisory Board of Tian Kang Bio Co., Ltd. It details the approval of a proposal regarding the use of idle funds by a subsidiary for cash management. The document includes voting results and confirms compliance with legal and regulatory requirements. It is not a full financial report, audit report, or earnings release. It is also not a notice of dividend, capital change, or management change. The document is a regulatory announcement related to corporate governance and financial management decisions but does not fit into more specific categories like AGM materials or proxy statements. Given its nature as a formal meeting resolution announcement, it best fits under Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories. The document length is short and contains no financial statements or detailed financial data, so it is not an Annual Report or Interim Report. Confidence is high due to clear identification of the document as a meeting resolution announcement.
2022-10-10 Chinese
2022年第三季度可转换公司债券转股情况的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the convertible bonds (可转换公司债券) of Tian Kang Bio Co., Ltd. It details the bond issuance, conversion prices, adjustments, and the changes in share capital due to bond conversions for the third quarter of 2022. The document includes specific bond codes, stock codes, regulatory approvals, and detailed shareholding changes due to bond conversions. It is not a full financial report but a regulatory announcement about bond conversion and share capital changes. The document length is 2684 characters, which is relatively short and focused on a specific capital/financing event. Therefore, it fits best under Capital/Financing Update (CAP) as it provides updates on convertible bond conversions and related share capital changes.
2022-10-10 Chinese
关于2022年9月份生猪销售简报
Regulatory Filings Classification · 95% confidence The document is a sales brief for September 2022 from Tian Kang Biological Co., Ltd., detailing sales volume, revenue, and reasons for changes. It is a short announcement (924 characters) providing interim sales data and risk warnings, without comprehensive financial statements or detailed analysis. It does not present a full quarterly or annual report, nor is it a certification or voting result. It is a periodic sales update, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2022-10-10 Chinese
关于控股子公司为母公司提供担保的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Tian Kang Biological Co., Ltd. regarding a guarantee provided by its controlling subsidiary to the parent company for a bank financing credit line. It includes details about the guarantee amount, terms, financial data summary, and compliance with regulatory requirements. The document is relatively short (1912 characters) and serves as a formal disclosure of a financing guarantee arrangement rather than a full financial report or detailed financial statements. It does not contain comprehensive financial results or management discussion but focuses on a specific capital/financing update related to guarantees and credit facilities. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2022-09-19 Chinese

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.